Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1207H
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
QL1207H is a high-dose aflibercept biosimilar developed by Qilu Pharmaceutical. It is a recombinant fusion protein that functions as a soluble decoy receptor, binding to vascular endothelial growth factor-A (VEGF-A), VEGF-B, and placental growth factor (PlGF). By sequestering these growth factors, QL1207H inhibits the activation of VEGF receptors, thereby suppressing pathological angiogenesis and reducing vascular permeability in the retina. It is currently being evaluated in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD), specifically comparing its efficacy and safety to the 8 mg high-dose formulation of the reference product, Eylea.
- Other names
- aflibercept biosimilar
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on QL1207H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1207H.